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ElectrolytesAbstract Various circulating biochemical markers are indicators of pathological state in leukemia
and its subtypes. Increased oxidative stress and decreased antioxidant factors portray clear image
associated with malignancies during subtypes of leukemia. In this research work we investigated
the inter-relationship among the subtypes of leukemia with circulating biochemical markers and oxi-
dative stress in the Pakistani population. This research work was conducted on a total number of 70
subjects in which 20 were control participants and 50 were suffering from leukemia and divided into
two subtypes (ALL and AML). Various circulating biomarkers were investigated including hemato-
logical, hepatic and renal proﬁles as well as oxidative stress markers, electrolytes and vitamins C
and E. Results show that vitamin E was found to be decreased in diseased sub-types (P< 0.05).
Assessment of biochemical markers and antioxidative status in ALL and AML patients 107Malondialdehyde (MDA) levels were very high in disease sub-types (ALL-B = 8.69 ± 1.59; ALL-
T = 8.78 ± 0.97; AML= 8.50 ± 1.29) compared to controls (1.22 ± 0.10; P< 0.05) while the
levels of antioxidants [superoxide dismutase (SOD), glutathione peroxidase (GPx), reduced
glutathione (GSH), catalase (CAT)], platelets, as well as electrolytes (Ca and Mg) were reduced in
patients suffering from leukemia (sub-types). Enhanced levels of oxidative stress (MDA) and
decreased levels of enzymatic and non-enzymatic antioxidants reﬂect the pathological state and
impaired cell control in patients suffering from leukemia (subtypes) and show a strong correlation
with oxidative stress, indicating that patients’ biological systems are under oxidative stress.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Acute myeloid leukemia (AML) is a disorder of hematopoietic
malignancy due to the accumulation of the blast and uncon-
trolled proliferation factors which really affects differentiation.
On the other hand, acute lymphoblastic leukemia (ALL) is the
most common childhood cancer, and the second most com-
mon cause of mortality in children aged 1–14 years.
Acute lymphoblastic leukemia ALL occurs approximately
ﬁve times more frequently than AML and accounts for about
78% of all childhood leukemias diagnosed (Charalambous,
2012). Approximately 3250 children under the age of 20 years
are diagnosed with leukemia each year, of about 2400 new
cases of ALL are diagnosed (Jensen et al., 2004). ALL is an
incurable disease due to the resistance toward treatment. There
are many factors which are involved to cause resistance from
chemotherapy which include oxidative stress due to the gener-
ation of reactive oxygen species (ROS) and presence of hypo-
diploid cells. Most common antioxidants include vitamins A,
C, and E, glutathione (GSH), and the enzymes superoxide dis-
mutase (SOD), catalase (CAT), glutathione peroxidase (GPx),
and glutathione reductase (GRx). Chemotherapy resistance is
a basic hurdle in the treatment of ALL patients (Mendivil-
Perez et al., 2012). The incidence of ALL in elderly patients
is 1.0 to 1.6 per 100,000 patients, which is much higher than
the patients 25–54 years old (0.6 to 0.7 per 100,000) according
to the surveillance epidemiology and end results study. In ALL
patients above 60 years of age the prognosis rate is very poor
due to some other correlated factors like, decreased bone mar-
row function, and other comorbidities but in children progno-
sis is better due to the introduction of central nervous system
treatment, hematopoietic stem cell transplant (HSCT), intensi-
ﬁed post remission therapy and molecular targeted therapy
such as imatinib mesylate (Shin et al., 2011).
Reactive oxygen species (ROS) are the heterogeneous
group of compounds which are generated by the mature mye-
loid lines in an innate response. ROS have an important role in
intracellular signaling process. An excessive production of
ROS can lead to oxidative stress which is quite clear in a num-
ber of hematopoietic malignancies including acute and chronic
leukemias but it is unclear that ROS are involved in the initi-
ation, progression and maintenance of diseases (Hole et al.,
2011). Oxidative stress which is caused by ROS is responsible
to cause DNA damage, because in normal conditions DNA-
repair mechanism is functional to repair the DNA. DNA dam-
age is not repaired properly in the oxidative stress which leads
to mutagenesis (Kryston et al., 2011). Moreover, MUC1-C is
an oncoprotein which suppresses the activity of the ROS.Inhibition of MUC1-C is directly associated with the increase
of ROS and depletion of glutathione (Yin et al., 2011).
2. Materials and methods
The study was conducted at the Institute of Molecular Biology
and Biotechnology (IMBB), the University of Lahore, and all
samples were collected from the Inmol Hospital, Lahore and
stored at 20 C. In this study a total number of 70 subjects
were selected in which 20 were normal healthy individuals
and 50 were leukemic patients which were divided into three
subgroups (ALL-B = 25; ALL-T = 11; AML= 14).
Informed consent was taken from all the persons participating
in this study. The study was also approved by the local ethics
committee of the University of Lahore.
2.1. Blood collection and laboratory investigation for
hematological parameters
First skin was cleaned thoroughly and sterilized with a 70%
alcohol swab (Kandall HealthCare, USA) and dried before
withdrawing 2 ml of peripheral blood by a 3 cc disposable syr-
inge (Becton Dickinson Pak) from enrolled subjects. For
hematological variables (white blood cells, hemoglobin and
platelets), blood was transferred to an ethylenediamine tetra
acetic acid (EDTA) coated purple-top test tube. Hematological
parameters including WBCs, Hb and platelets were estimated
by a Hematological Analyzer.
2.2. Processing of blood sample for other all clinical parameters
6 ml of venous blood was taken from each subject and quickly
transferred into a tube. The tubes were marked with the code
assigned to the subject. Samples were quickly transported to
the laboratory for further processing. After blood sample col-
lection, sample tubes were centrifuged for ﬁfteen minutes at
4000 rpm to obtain a clear serum. Thus overwhelmingly tests
were carried out within six hours after the collection.
ALT, AST, ALP, creatinine, phosphate, uric acid, K, Ca,
Na, Mg and BUN were estimated by direct kit method using
precipitants of Spinreact Co, Spain and estimation of vitamins
(C and E) was carried out through commercially available,
Human Diagnostic Kit by Spinlab - Spinreact clinical analyzer.
Superoxide dismutase (SOD) and catalase activities were
measured by Kakkar et al. (1984), and Aebi and Bergmeyer
(1983) respectively. Reduced glutathione and glutathione per-
oxidase were evaluated by the methods of Moron et al.
Table 1 Levels of different variables (bio-chemicals and antioxidative markers) in subtypes of leukemia.
Variables Control Disease sub-types P value
(n= 20) ALL-B (n= 25) ALL-T (n= 11) AML (n= 14)
ALT 20.00 ± 5.17 86.00 ± 36.07* 89.54 ± 44.80* 83.71 ± 24.61* 0.001
AST 24.20 ± 5.40 56.08 ± 18.63* 59.00 ± 15.17* 56.71 ± 17.62* 0.001
ALP 194.97 ± 32.45 377.95 ± 34.76* 367.59 ± 41.14* 375.97 ± 31.86* 0.001
MDA 1.22 ± 0.10 8.69 ± 1.59* 8.78 ± 0.97* 8.50 ± 1.29* 0.001
SOD 0.51 ± 0.18 0.14 ± 0.12* 0.17 ± 0.11* 0.15 ± 0.11* 0.001
GSH 9.23 ± 1.44 2.15 ± 0.74* 2.38 ± 0.66* 2.33 ± 0.91* 0.001
Catalase 4.07 ± 0.84 0.73 ± 0.67* 0.83 ± 0.32* 0.77 ± 0.58* 0.001
NO 10.64 ± 1.83 19.71 ± 1.75* 20.83 ± 2.32* 20.26 ± 1.77* 0.001
Creatinine 1.04 ± 0.18 3.03 ± 0.43* 3.13 ± 0.27* 3.10 ± 0.41* 0.001
BUN 13.65 ± 2.34 33.88 ± 5.55* 34.36 ± 7.18* 33.78 ± 4.49* 0.001
K 3.86 ± 0.55 6.02 ± 0.93* 5.91 ± 0.90* 6.40 ± 1.04* 0.001
Ca 8.79 ± 0.90 7.49 ± 1.06* 7.49 ± 1.06* 7.00 ± 1.25* 0.001
Na 139 ± 5.22 167 ± 12.06* 161 ± 6.03* 163 ± 9.17* 0.001
Mg 1.76 ± 0.21 1.41 ± 0.21* 1.40 ± 0.19* 1.40 ± 0.27* 0.001
Phosphate 3.36 ± 0.89 5.75 ± 0.50* 5.77 ± 0.77* 5.95 ± 0.49* 0.001
Uric acid 3.77 ± 0.78 10.35 ± 1.49* 10.71 ± 1.13* 10.48 ± 1.76* 0.001
WBC 7.60 ± 1.39 50.94 ± 28.20* 63.48 ± 33.90* 53.41 ± 27.24* 0.001
Hb 13.96 ± 0.94 9.64 ± 1.71* 9.16 ± 1.44* 9.43 ± 2.24* 0.001
Platelets 217 ± 20.45 83.40 ± 21.03* 85.27 ± 24.37* 77.21 ± 19.12* 0.001
GPx 0.60 ± 0.32 0.29 ± 0.13* 0.33 ± 0.14* 0.33 ± 0.19* 0.001
Vit.C 0.38 ± 0.19 0.49 ± 0.13ns 0.46 ± 0.10ns 0.48 ± 0.90ns 0.145
Vit.E 0.46 ± 0.11 0.22 ± 0.09* 0.24 ± 0.13* 0.20 ± 0.10* 0.001
Hb = g/dl, ALT = IU/L, AST = IU/L, ALP = IU/L, Creatinine = mg/dL, MDA= nM/ml, SOD= ng/ml, GSH=mg/dl, CAT= lM/mol
of protein, Na+=mEq/L, K+=mEq/L, Ca++=mEq/L,Mg++= 1.8–3 mg/dL, Phosphate = mg/dL, Uric acid = mg/dL,WBCs = ·109/
L, platelets = ·109/L, GPx = lmol/ml, Vit. C = lg/ml, Vit. E = lg/ml, BUN=mg/dL, NO= lM/L,
* Signiﬁcant P< 0.05).
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aldehyde (MDA) and nitric oxide (NO) were measured by the
methods of Ohkawa et al. (1979) and Moshage et al. (1995)
respectively.
2.3. Data analysis
SPSS version18 was used for statistical analysis. Results were
expressed by mean and standard deviation and the correlations
between various parameters and different subgroups were also
determined. P< 0.05 was considered as statistical signiﬁcance.3. Results
The leukemic subjects were sub-divided into different sub types
and showed a highly signiﬁcant difference among themselves
and with controls. All the results are summarized in Table 1.
The ALT level in ALL-T sub-type (89.54 IU/L) was surpassed
as compared to ALL-B (86.00 IU/L) and AML (83.71 IU/L)
respectively. In case of AML involvement of the liver is rarely
reported. In a number of previous research studies it is
reﬂected that cholestasis and obstructive jaundice are involved
in elevated hepatic proﬁle. In reported cases it was analyzed
that the patients receiving traditional combined drug therapy
of anthracyclines and cytarabine have an elevated hepatic pro-
ﬁle in AML. In case of ALL elevated levels of ALT and AST
are associated with completion of chemotherapy as compared
to the values of ALT and AST before chemotherapy. Elevatedlevels of transaminases were common at the initial stages of
ALL and caused due to the injury by the leukemic cell
inﬁltration. Elevated levels of AST were observed in ALL-T
(59.00 IU/L), AML (56.71 IU/L) and ALL-B, (56.08 IU/L)
respectively.
From ALL group in the case of ALL-T elevated levels of
MDA were observed (8.78 lmol/ml) than other sub-groups
[AML and (ALL-B)] ALL-B (8.69 lmol/ml) and in AML
(8.50 lmol/ml). Decreased levels of anti-oxidant enzyme
highlighted the impaired anti-oxidant system and ROS accu-
mulation. SOD levels were assessed on the basis of disease
sub-type, ALL-T had more accelerated values (0.17 ng/ml)
than the values of the other groups (AML 0.15 ng/ml and
ALL-B 0.14 ng/ml) respectively. In the case of ALL-T the
levels of GSH were 2.38 mg/dl and slightly greater than
AML levels of GSH (2.33 mg/dl), while the value of ALL-
B type was less than the rest of the others (2.15 mg/dl)
respectively. Decreased plasma levels of reduced GSH were
due to the over-production of ROS. The non-enzymatic
antioxidant may take up by the hematopoietic cells to min-
imize the oxidative stress. Reduced GSH expression is com-
mon in acute leukemia patients such as in the case of ALL.
The levels of catalase of ALL-T were more elevated than
other sub-types (0.83 lmol/mol of protein) while the other
groups have ALL-B (0.73 lmol/mol of protein) and
AML (0.77 lmol/mol of protein). Similarly in the case of
NO, ALL-T the values were more elevated (20.83 lmol/L)
than other groups AML (20.26 lmol/L) and ALL-B
(19.71 lmol/L) respectively.
Table 2 Correlation among various circulating biomarkers in
subtypes of leukemia.
Group Correlation coeﬃcient (r) P value
MDA vs SOD 0.457* 0.001
MDA vs CAT 0.251 0.079
MDA vs GSH 0.021 0.886
MDA vs ALT 0.456* 0.001
SOD vs CAT 0.383* 0.006
SOD vs GSH 0.061 0.672
GSH vs Vit. E 0.285* 0.045
CAT vs Phosp 0.310* 0.028
ALT vs AST 0.631* 0.000
ALT vs Vit. E 0.329* 0.02
ALT vs Ca 0.344 0.015
* Signiﬁcant P< 0.05).
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The present research work is based on two acute sub-types of
leukemia; ALL (ALL-T & ALL-B) and AML. Oxidative stress
is caused due to the imbalance, which is present among the
ROS generation and antioxidant activity (Ott et al., 2007).
Antioxidants are working in the human body in the form of
antioxidant defense system against the ROS generation.
Enzymes, which include GPx, SOD and catalase, have the abil-
ity to degrade the superoxide into H2O2 (Paes et al., 2001).
Lipid peroxidation is accelerated by the oxidation of lipid; as
a result the production of MDA is accelerated. The elevated
levels of MDA act like a marker of oxidative stress in the
human body in the form of lipid peroxidation (Termini,
2000). The plasma MDA levels act as an important biomarker
of leukemia having diagnostic and prognostic role indicating
disease progression (Ahmad et al., 2008). Serum protein car-
bonylation and MDA levels are higher which indicates that
the ALL patients have impaired plasma antioxidant status.
In case of AML increased amount of ROS and decreased con-
centration of antioxidant enzymes are an important feature of
AML relapse (Zhou et al., 2010).
In the present study results shows that MDA level increases
as compared to the control/normal which is a marker of oxida-
tive stress. The antioxidant enzyme impairment in leukemia
and in other cancers is a prominent feature. The coefﬁcient
of correlation in MDA vs SOD, r= 0.476*, which shows
that O2
 may be produced in this disease/condition, and resul-
tantly the H2O2 is the end product of this cascade; So, H2O2
must be neutralized and catalase is the main player for this
entity as reﬂected by the correlation coefﬁcient (SOD vs
CAT r= 0.383*), increases to minimize the oxidative stress.
It is clear that the correlation coefﬁcient of MDA vs CAT,
r= 0.251 which is not as much higher. It reﬂects that some
other mechanism/pathways are also involved to minimize the
oxidative stress possibly GPx is involved to minimize the oxi-
dative stress. MDA vs GSH, r= 0.021 GSH levels were also
decreased as compared to the MDA, have an insigniﬁcant cor-
relation between MDA and GSH (0.86) (Table 2).
The present study is in agreement with the previous studies
that in the case of leukemias including ALL and AML the lev-
els of SOD are lower than the normal patients. In case ofdisease the impaired antioxidant system is the primary cause
behind the accumulation of ROS. The accelerated amount of
ROS further affects a number of growth and proliferation
pathways. SOD vs GSH, r= 0.061 have inverse as well as
weak correlation, due to the impairment of antioxidant system.
There was an insigniﬁcant correlation (0.672) observed
between SOD and GSH. And SOD vs CAT r= .383* have
weak correlation coefﬁcient.
The antioxidant enzymes and essential micronutrients are
in minute amount in leukemics that is a ﬁrst line of defense
especially in CML patients (Pande et al., 2012). GSH
deﬁciency may indeed be responsible for the immunological
non-responsiveness under the excessive antigenic stimulation
by non-professional stimulator cells. Reduced GSH is an
important key factor and has an important role as scavenger
of ROS and an important constituent of the thiol pool. The
major key role of GSH is to work as a non-enzymatic reducing
agent to support the key cysteine thiol side in the reduced state
on the surface of the protein. GSH is involved in DNA synthe-
sis and repair. In the case of leukemia reduced levels of GSH
reﬂect the depletion of non-enzymatic antioxidant reserve. It
reﬂects that the GSH depletion, normally acts as an antioxi-
dant factor, while decreased plasma levels of GSH may be
due to the over-production of ROS in hematopoietic cells.
ROS play critical role in tumor metastasis. ROS are capable
of oxidizing different target molecules such as protein kinase
C (PKC) and protein tyrosine phosphatase (PTPs) which have
an important role in tumor invasion. Mitogen activated pro-
tein kinase (MAPK) and p21 regulated by ROS and Philadel-
phia chromosome which is produced by the fusion proteins.
All these factors reﬂect that these signaling pathways interre-
late with the up-regulated expression of growth and prolifera-
tion (Ahmad et al., 2008).
GSH and vitamin E have a coefﬁcient correlation, GSH vs
Vit. E, r= 0.285* is weak and inverse correlation between
them, and are statistically signiﬁcant (P= 0.045). So, it
reﬂects that GSH and vitamin E are involved in antioxidant
activity and impairment in physiological system causes disease.
ROS are involved to cause the tissue injuries. An increased
amount of the ROS causes cell death by apoptosis or by necro-
sis (Xavier et al., 2012). Research suggests that a small amount
of the catalase is normally present in tissues (Marklund et al.,
1982). The levels of anti-oxidant enzymes are signiﬁcantly
decreased in the case of acute leukemic subject erythrocytes.
In simple words it is described as antioxidant level decreases
and accumulation of oxidative stress in the form of ROS is evi-
dent (Demir et al., 2010). The levels of antioxidant enzymes,
which include catalase, GPx and SOD, are lower in lympho-
cytes of ALL patients than control/normal (Mates and
Sanchez-Jimenez, 2000). The reduced activity of the selenium
dependent enzyme GPx in blood is associated with the
increased risk of poor prognosis of cancer. The phosphoryla-
tion cascade leads to the activation of MAPKs and NF-jB
(Mates and Sanchez-Jimenez, 2000). SOD and catalase activity
reduced in the case of chronic leukemias as compared to the
GPx activity. Zhou et al. (2010) reported that that the activity
of catalase and GPx is reduced in the case of acute leukemias
as compared to the control/normal individuals due to the
impaired antioxidant status in serum.
Blood urea nitrogen (BUN) behaves as an important mar-
ker in disease state. BUN levels were elevated in leukemia
patients compared to the control group (P< 0.005). Research
110 M. Rasool et al.studies describe that not only in acute leukemias but also in
chronic leukemias like in case of CLL (chronic lymphocytic
leukemia) pneumonia, BUN was a major pulmonary compli-
cation. Patients have higher levels of BUN and severe neutro-
penia which were correlated with the mortality of leukemia
patients (Ahmed et al., 2003).
Antioxidant enzymes interact with the free radicals in dif-
ferent ways, by controlling the chain of reactions. The exam-
ple of the antioxidant includes SOD, CAT, GPx, vitamin A,
E, and uric acid. In the case of leukemic cells higher levels
of ROS are produced than normal cells. Deepti et al.
(2012) reported that the vitamin E and A along with
SOD, CAT, GPx, are signiﬁcantly reduced in leukemia.
So, these ﬁnding suggest that antioxidant enzymes along
with vitamin E and A protects the biological system against
ROS. In leukemia, levels of vitamin E are lower than nor-
mal control persons, not only in the case of ALL and
AML but also in CLL and CML. One main reason behind
this is the malnutrition because the under-nourished persons
have impaired immune and hematopoietic systems. Oxidative
stress in leukemic patients is another basic causative factor
for the deﬁciency of vitamin E correlated with the elevated
accumulation of ROS in the biological system. Segal et al.
(2010) reported elevated levels of transaminases and the
causative factors behind that accelerated expression are, high
WBC count at diagnosis, bulky disease, older age and T-cell
leukemia. Like in the case of ALL elevated transaminases
are due to hepatic injury from leukemic inﬁltrates (Segal
et al., 2010).5. Conclusion
It is concluded from this study that enhanced levels of oxida-
tive stress (MDA) and decreased levels of enzymatic (SOD,
GPx and CAT) and non-enzymatic antioxidants (vitamin E
and GSH) reﬂect pathological state and impaired cell control
in subtypes (ALL and AML) of leukemia depending upon
the alterations in genetic makeup as well as have a strong cor-
relation with oxidative stress, showing that patients’ biological
systems are under oxidative stress. Levels of antioxidants must
be regularly evaluated during the treatment of patients with
leukemia.Conﬂict of interest
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